1. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among methods. J Clin Endocrinol Metab. 2000;85:4426-4433.
2.
2. Freemark M. Pharmacologic approaches to the prevention of type 2 diabetes in high risk pediatric patients. J Clin Endocrinol Metab. 2003;88:3-13.
3.
3. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis. JAMA. 2000;283:221-228.
4.
4. Fernandez-Real JM, Ricart W. Insulin resistance and inflammation in an evolutionary perspective. The contribution of cytokine genotype/phenotype to thriftiness. Diabetologia. 1999;42:1367-1374.
5.
5. Straczkowski M, Dzienis-Straczkowski S, Stepien A, et al. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factoroc system. J Clin Endocrinol Metab. 2002;87:4602-4606.
6.
6. Barbeau P, Litaker MS, Woods KF, et al. Hemostatic and inflammatory markers in obese youth: effects of exercise and adiposity. J Pediatr. 2002; 141:415-420.
7.
7. Freedman DS, Serdula MK, Srinivasan SR, Bereson GS. Relation of circumferences and skinfold thicknesses to lipid and insulin concentrations in children and adolescents: the Bogalusa Heart Study. Am J Clin Nutr. 1999;69:308-317.
8.
8. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA. 2002;288:1728-1732.
9.
9. Dabelea D, Hanson RL, Bennett PH, et al. Increasing prevalence of Type II diabetes in American Indian children. Diabetologia. 1998;41:904-910.
10.
10. Ibanez L, Potau N, Zampolli M, et al. Hvperinsulinemia in postpubertal girls with a history of premature pubarche and functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1996;81:1237-1243.
11.
11. Mauras N, WAelch S, Rini A, Haymond MW. Ovarian hyperandrogenism is associated with insulin resistance to both peripheral carbohydrate and whole-body protein metabolism in postpubertal young females: a metabolic study. J Clin Endocrinol Metab. 1998;83: 1900-1905.
12.
12. Shepherd PR, Kahn BB. Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. N Eng1 j Med. 1999;341:248-257.
13.
13. Eckel RH. Insulin resistance: an adaptation for weight maintenance. Lancet. 1992;340:1452-1453.
14.
14. Catalano PM, Drago NM, Amini SB. Maternal carbohydrate metabolism and its relationship to fetal growth and body composition. Am J Obstet Gynecol. 1995;172:1464-1470.
15.
15. Nguyen TT, Keil MF, Russell DL, et al. Relation of acanthosis nigricans to hyperinsulinemia and insulin sensitivity in overweight African-American and white children.J Pediatr2001;138:474-480.
16.
16. Silfen ME, Manibo AM, Mc Mahon DJ, et al. Comparison of simple measures of insulin sensitivity in young girls with premature adrenarche: the fasting glucose to insulin ratio may be a simple and useful measure. J Clin Endocrinol Metab. 2001;86:2863-2868.
17.
17. Laakso M. How good a marker is insulin level for insulin resistance?Am J Epidemiol. 1993;137:959-965.
18.
18. Mather KJ, Hunt AE, Steinberg HO, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab. 2001;86:5457-5464.
19.
19. Quon MJ. Limitations of the fasting glucose to insulin ratio as an index of insulin sensitivity. J Clin Endocrinol Metab. 2001;86:4615-4616.
20.
20. Bergman RN, Prager R, Volund A, Olefsky M. Equivalence of insulin sensitivity index in man derived by the minimal model and euglycemic glucose clamp. J Clin Invest. 1987;79:790-800.
21.
21. Uwaifo GI, Nguyen TT, Keil MF, et al. Differences in insulin secretion and sensitivity of Caucasian and African-American prepubertal children. J Pediatr2002;140:673-680.
22.
22. Mathews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and,β-cell function from fasting glucose and insulin concentrations in man. Diabeologia. 1985;28:412-419.
23.
23. Berntorp K, Trell E, Thorell J, Hood B. Relation between plasma insulin and blood glucose in a cross-sectional population study of the oral glucose tolerance test. Acta Endocrinol. 1983;102:549-556.
24.
24. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:2694-2698.
25.
25. Duncan GE, Hutson AD, Stacpoole PW. QUICKI does not accurately reflect changes in insulin sensitivity with exercise training. J Clin Endocrinol Metab. 2001;86:4115-4119.
26.
26. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402-2410.
27.
27. Perseghin G, Caumo A, Caloni M, et al. Incorporation of the fasting plasma FFA concentration into QUICKI improves its association with insulin sensitivity in non-obese individuals. J Clin Endocrnol Metab. 2001;86:4776-4781.
28.
28. Robbins DC, Andersen L, Bowsher R, et al. Report of the American Diabetes Association's Task Force on standardization of the insulin assay. Diabetes. 1996;45:242-256.
29.
29. Oberfield SE. Metabolic lessons from the study of young adolescents with polycystic ovary syndrome: is insulin, indeed, the culprit?J Clin Endocrinol Metab. 2000;85:3520-3525.
30.
30. Palmert MR, Gordon CM, Kartashov Al, et al. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:1017-1023.
31.
31. Fremark M, Bursey D. The effect of metformin on body mass index and glucose tolerance in obese adolescents with fasting hvperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107:e55-e55.
32.
32. Kay JP, Alemzadeh R, Langley G, et al. Beneficial effects of metformin on normoglycemic morbidly obese adolescents. Metabolism. 2001;50:2094-2099.
33.
33. Ehrmann DA, Scvhneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycvstic ovary syndrome. J Clin Endocrinol Metab. 1997;82:2108-2116.
34.
34. Velazquez EM, Mendoza S, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with polycystic ovary syndrome. Metabolism. 1997;46:454-457.
35.
35. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344:1343-1350.